Premium
Biphenotypic acute leukaemia: a case series
Author(s) -
Aribi Ahmed,
BuesoRamos Carlos,
Estey Eli,
Estrov Zeev,
O'Brien Susan,
Giles Francis,
Faderl Stefan,
Thomas Deborah,
Kebriaei Partow,
GarciaManero Guillermo,
Pierce Sherry,
Cortes Jorge,
Kantarjian Hagop,
Ravandi Farhad
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06634.x
Subject(s) - medicine , myeloid leukaemia , myeloid , chromosomal abnormality , gastroenterology , oncology , immunology , karyotype , biochemistry , chemistry , chromosome , gene
Summary Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co‐expressed B‐lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.